BioTransfer is a "one-stop shop" for companies looking for new therapeutics and diagnostics as well as platform technologies that can improve or accelerate their R&D and biopharmaceutical production. Each 10-minute presentation from McGill University's OTT and NRC-BRI will focus on the business opportunities offered by these technologies.
|
|
Session 4A: Room A-34A
Chair: Mr. Yves Quenneville ,
Business development officer
NRC Biotechnology Research Institute, Canada
|
Session 4B: Room A-34B
Chair: Mr. Pierre Bourassa,
Industrial technology advisor
NRC Industrial Research Assistance Program, Canada
|
|
14:00 |
Novel Anti-Mitotic Peptides for the treatment of Cancer
Dr. Louise O'Donoughue, McGill University (04086) |
Computer-Aided Diagnosis Software for Neurological Diseases
Dr. Francoys Labonté, McGill University (04062) |
|
14:10 |
Peptides and proteins wound healing agents
Dr. John DiMaio, McGill University (04025) |
Carrier proteins for peptide production
Dr. Feng Ni, NRC-BRI (11391) |
|
14:20 |
Hybrid compounds for the treatment of refractory tumors
Dr. Michael Stern, McGill University (01057) |
High-Throughput Proteomics Pipeline
Dr. Francoys Labonté, McGill University (06013) |
|
14:30 |
Optimized soluble receptor as diagnostic and therapeutic tool
Dr. Maureen O'Connor-McCourt, NRC-BRI (11817) |
Assays for protein-protein interaction in the cytoplasm and/or on plasma membrane
Dr. Malcolm Whiteway, NRC-BRI (11681) |
|
14:40 |
Clusterin antibodies for cancer diagnostic and therapy
Dr. Maureen O'Connor-McCourt, NRC-BRI (11705) |
A cumate switch for protein production
Dr. Bernard Massie, NRC-BRI (11648) |
|
14:50 |
GIFT15, a biological immunosuppressant for systemic and ex-vivo treatment
Dr. Jacques Galipeau, McGill University (06087) |
Methylobacterium expression system
Dr. Carlos Miguez, NRC-BRI (11725) |
|
15:00 |
Cell Permeable Peptide for Treatment of Allergic Airway Diseases
Dr. Elizabeth Fixman, McGill University (05003) |
Expression systems for production of recombinant proteins in mammalian cells
Dr. Yves Durocher, NRC-BRI (11565) |
|
15:10 |
Peptide inhibitors of thrombin as potent anticoagulants
Dr. Feng Ni, NRC-BRI (11388) |
Baculovirus mediated transgene for protein expression
Dr. Alaka Mullick, NRC-BRI (11770) |
|
15:20 |
Biomolecular tweezers for drug discovery
Dr. Dmitri Tolkatchev, NRC-BRI (11615) |
Large scale transient transfection in mammalian cells
Dr. Yves Durocher, NRC-BRI (11266) |
|
15:30 |
Novel Vaccine Adjuvant
Dr. John DiMaio, McGill University (06048) |
Low cost high throughput antibody production
Dr. Astrid Reimann
, McGill University (06099) |
|
15:40 |
Nucleic acid hairpins as inhibitors of HIV RNAse H
Dr. Masad J. Damha
, McGill University (03050) |
Peptides to facilitate drug delivery
Dr. Orest Blaschuk
, McGill University (05012) |
|
15:50 |
Detection of intact recombinant viruses
Dr. Julia Transfiguracion, NRC-BRI (11622) |
FITTED 1.5: A Molecule Docking Software Program
Dr. Nicolas Moitessier, McGill University (06119) |
|
16:00 |
Closing Remarks - Session 4A
Mr. Yves Quenneville,
Business development officer
NRC Biotechnology Research Institute, Canada |
Closing Remarks - Session 4B
Chair: Mr. Pierre Bourassa,
Industrial technology advisor
NRC Industrial Research Assistance Program, Canada
|
|
 |
|
|
